| *Sponsored
(NYSE American: MAIA) Continues To Ride High On Breaking News (Tests $2.00 Psychological Resistance)
June 5th Dear Reader,
Could $2.00 psychological resistance on MAIA Biotechnology, Inc. (NYSE American: MAIA)'s chart be on the verge of breaking down?
After breaking through that level in pre-market and testing the same level after the bell, potential chart resistance at $2.00 could be on the verge of a possible breakdown.
And as I mentioned previously, MAIA has already found itself above 4 key technical chart levels which signals support may be growing in droves.
Furthermore, the company just dropped breaking news today!
Take a look: MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
From the article:
"It is gratifying to see that our treatment further extends lives for these hard-to-treat patient populations, especially in third-line NSCLC treatment where patients are most resistant to therapy," said MAIA Chairman and CEO Vlad Vitoc, M.D. "This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape."
Take a moment to review my initial (NYSE American: MAIA) report below and consider this biotech profile for your watchlist. -----
Attention is being drawn to a significant development in the treatment of advanced non-small cell lung cancer.
A novel therapeutic approach, recently featured at a leading international oncology conference, has shown promising results in patients unresponsive to current immunotherapies.
This innovative method targets telomeres within cancer cells, resulting in substantial tumor regression and heightened immune activity.
Clinical findings are attracting recognition from experts and may signal a shift in the management of resistant lung cancer cases.
Ongoing clinical trials will further clarify the potential of this therapy, making it an area worth monitoring closely as new data emerges.
Another thing to monitor closely? How about a $14 analyst target?
From Wednesday's close, this NYSE American profile may be eyeing a healthy 600+% potential upside to that target.
Oh. And this isn't the first time I've alerted this profile.
When I brought this one to your attention back in 2024, it erupted, running approximately 275+% in a few month span.
All of this and more is why this Biotech is topping my watchlist:
*MAIA Biotechnology, Inc. (NYSE American: MAIA)*
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
Their lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
And based on multiple potential breakout catalysts, MAIA should be considered as watchlist material. Check them out:
#1. One Analyst's Target Suggests Over 600% Potential Upside From MAIA's Current Chart Levels.
#2. Volatility Could Be In Full Force Based On MAIA's Low Float.
#3. A Shareholder Letters Points To The Potential For Key Milestones On The Horizon.
#4. MAIA’s THIO Shows Promise For Resistant NSCLC At ASCO 2025.
But more on those in a second...
MAIA's First-In-Class Cancer Telomere Targeting Agent: THIO
THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development.
Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s in vitro activity has been studied in models of several tumor types with active telomerase.
A New Therapeutic Strategy
THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death.
Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models in vivo, and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment.
These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining their telomere-targeted therapy with immunotherapy (Mender et al., 2020).
Clinical Development
MAIA is currently advancing THIO in a Phase 2 clinical study in Non-Small Cell Lung Cancer (NSCLC). This is the first study to test THIO’s immune system activation followed by administration of the checkpoint inhibitor cemiplimab, allowing for the immune activation and PD-1 sensitivity to take effect. The trial will test the hypothesis that lower doses of THIO administered prior to Libtayo treatment would enhance and prolong responses in subjects with advanced NSCLC who did not respond or progressed after first-line treatment with a checkpoint inhibitor.
Second-Generation
Telomere Targeting Agents
MAIA has initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity.
MAIA's Pipeline
The company's pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers: | 
